Lilly, NextCure Partner on Immuno-Oncology Medicines
November 07, 2018
The multi-year collaboration will incorporate NextCure's proprietary FIND-IO platform, a technology designed to identify novel cell-surface molecular interactions that drive functional immune responses in the tumor microenvironment and other disease sites.